Association of Kalrn, Adipoq, and Fto Gene Polymorphism in Type 2 Diabetic Patients With Coronary Artery Disease: Possible Predisposing Markers Publisher Pubmed



Mofarrah M¹ ; Ziaee S² ; Pilehvarsoltanahmadi Y¹ ; Zarghami F¹ ; Boroumand M³ ; Zarghami N¹ Show Affiliations
Source: Coronary Artery Disease Published:2016

Abstract

Objectives Recently, several genes have been introduced as potential genetic markers for diabetes mellitus and coronary artery diseases (CAD). Methods In this case-control study, the associations of rs2241766 T/G of ADIPOQ, rs9289231 T/G of KALRN, and rs9939609 A/T of FTO polymorphisms with genetic susceptibility to CAD in type 2 diabetic (T2D) patients were investigated. A total of 224 T2D patients undergoing coronary angiography were randomly recruited into the study. Of the total diabetic patients, 152 were also diagnosed with CAD, whereas the rest were control participants. Genotyping of single-nucleotide polymorphisms was performed by high-resolution melting analysis. Results Genotype analysis showed that the minor allele (G) frequency of rs2241766 ADIPOQ was statistically significant in the CAD group compared with the control group [odds ratio (OR), 2.779; 95% confidence interval (CI), 1.403-5.504; P=0.003]. Also, it was found that the minor allele (G) frequency of rs9289231 KALRN was significantly associated with the risk of CAD (OR, 2.098; 95% CI, 1.096-4.017; P=0.025). In addition, no significant association was observed between the minor allele (A) of the FTO rs9939609 polymorphism and CAD (OR, 1.088; 95% CI, 0.578-2.015; P=0.788). It is speculated that the GG genotype and the G allele of the rs9289231 polymorphism of KALRN and the rs224766 polymorphism of ADIPOQ genes may be considered genetic risk factors for CAD in T2D patients and genetic variations of these genes may play a major role in the process of these disorders. Conclusion Our case-control study in the Iranian population suggested a possible association between the mentioned single-nucleotide polymorphisms and CAD in T2D patients. However, further replication studies and comprehensive meta-analyses are required. © 2016 Wolters Kluwer Health, Inc. All rights reserved.